Literature DB >> 7579381

Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma.

P R Koduru1, M Zariwala, M Soni, J Z Gong, Y Xiong, J D Broome.   

Abstract

B-cell non-Hodgkin's lymphoma (NHL) is a heterogeneous lymphoid malignancy consisting of several histologic types. Alterations in proto-oncogenes caused by reciprocal chromosome translocations have been implicated in the etiology of specific histologic groups. In this study, we examined the contribution of the cell cycle inhibitor genes P15, P16, and P18 to pathogenesis in a large panel of 209 cytogenetically characterized B-cell NHL tumors representing varied histologic groups. We identified the homozygous deletion of P15 and P16 genes in 13 tumors from 12 patients, all belonging to diffuse large-cell histology; 10 had this diagnosis made on presentation, 1 had transformed from small lymphocytic lymphoma, and 1 had transformed from Hodgkin's disease. Tumor-specific point mutations were not identified in the coding regions of these genes. Cytogenetically, chromosome 9p was normal in all but one tumor. On the other hand, eight tumors hemizygous for 9p by cytogenetic analysis showed wild-type configuration of these genes. Our study, therefore, indicates that deletion of P15 and P16 occurs in about 15% of diffuse large-cell NHL and is not usually detected by cytogenetic analysis. P18 was wild-type in all tumors including the 13 tumors hemizygous for 1p.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579381

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression.

Authors:  R Villuendas; M Sánchez-Beato; J C Martínez; A I Saez; B Martinez-Delgado; J F García; M S Mateo; L Sanchez-Verde; J Benítez; P Martínez; M A Piris
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

Review 2.  Genetic abnormalities in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.

Authors:  M Merup
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

3.  Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking.

Authors:  Daniel H Lachance; Ping Yang; Derek R Johnson; Paul A Decker; Thomas M Kollmeyer; Lucie S McCoy; Terri Rice; Yuanyuan Xiao; Francis Ali-Osman; Frances Wang; Shawn M Stoddard; Debra J Sprau; Matthew L Kosel; John K Wiencke; Joseph L Wiemels; Joseph S Patoka; Faith Davis; Bridget McCarthy; Amanda L Rynearson; Joel B Worra; Brooke L Fridley; Brian Patrick O'Neill; Jan C Buckner; Dora Il'yasova; Robert B Jenkins; Margaret R Wrensch
Journal:  Am J Epidemiol       Date:  2011-07-08       Impact factor: 4.897

4.  Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.

Authors:  Kristie A Blum; Anjani Advani; Louis Fernandez; Richard Van Der Jagt; Joseph Brandwein; Suman Kambhampati; Jeannine Kassis; Melanie Davis; Claire Bonfils; Marja Dubay; Julie Dumouchel; Michel Drouin; David M Lucas; Robert E Martell; John C Byrd
Journal:  Br J Haematol       Date:  2009-08-31       Impact factor: 6.998

5.  Effect of p16 on glucocorticoid response in a B-cell lymphoblast cell line.

Authors:  Sun-Young Kim; Kyung-Yil Lee; Dae-Chul Jeong; Hak-Ki Kim
Journal:  Korean J Pediatr       Date:  2010-07-31

6.  Knocking down CDK4 mediates the elevation of let-7c suppressing cell growth in nasopharyngeal carcinoma.

Authors:  Zhen Liu; Xiaobin Long; Cheng Chao; Chen Yan; Qiangyun Wu; Shengni Hua; Yajie Zhang; Aibing Wu; Weiyi Fang
Journal:  BMC Cancer       Date:  2014-04-21       Impact factor: 4.430

7.  Primary malignant lymphoma of the brain: demonstration of frequent p16 and p15 gene deletions.

Authors:  T Kumanishi; S Zhang; T Ichikawa; S Endo; K Washiyama
Journal:  Jpn J Cancer Res       Date:  1996-07

Review 8.  Cyclin-dependent kinase inhibitors in malignant hematopoiesis.

Authors:  Alessia Schirripa; Veronika Sexl; Karoline Kollmann
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.